Share Email Print
cover

Journal of Biomedical Optics

Optical molecular imaging of lymph nodes using a targeted vascular contrast agent
Author(s): Kai Licha; N. Debus; S. Emig-Vollmer; B. Hofmann; M. Hasbach; D. Stibenz; S. Sydow; Michael Schirner; Bernd Ebert; Diethard Petzelt; C. Bührer; W. Semmler; R. Tauber
Format Member Price Non-Member Price
PDF $20.00 $25.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

We develop a highly specific antibody-dye conjugate for optical imaging of peripheral lymph nodes. The contrast agent consists of the monoclonal antibody recognizing endothelial ligands for the lymphocyte homing receptor L-selectin, MECA-79, and a near-infrared (near-IR) fluorescent indotricarbocyanine dye. The targeting and biodistribution behavior of MECA-79 is studied after radio-iodination and intravenous injection into mice demonstrating specific uptake in lymph nodes and accumulation in high endothelial venules (HEV). After conjugation of MECA-79 with indotricarbocyanine dye, the fluorescence imaging properties of the MECA-79 dye conjugate are examined by intravenous injection in nude mice and laser-induced fluorescence whole-body imaging in vivo. The MECA-79 antibody-dye conjugate accumulates in peripheral lymph nodes, whereas an isotype antibody-dye conjugate does not. Specific lymph node near-IR fluorescent signals become detectable within minutes after injection, and stable imaging persists for more than 24 h. The results demonstrate that vascular targeting of endothelial expression of glyocproteins is feasible to visualize the accumulation of near-IR fluorescent MECA-79 in lymph nodes, making this technology potentially useful to characterize processes of inflammation.

Paper Details

Date Published: 1 July 2005
PDF: 6 pages
J. Biomed. Opt. 10(4) 041205 doi: 10.1117/1.2007967
Published in: Journal of Biomedical Optics Volume 10, Issue 4
Show Author Affiliations
Kai Licha, Schering AG (Germany)
N. Debus, Schering AG (Germany)
S. Emig-Vollmer, Schering AG (Germany)
B. Hofmann, Schering AG (Germany)
M. Hasbach, Schering AG (Germany)
D. Stibenz, Schering AG (Germany)
S. Sydow, Schering AG (Germany)
Michael Schirner, Schering AG (Germany)
Bernd Ebert, Physikalisch-Technische Bundesanstalt (Germany)
Diethard Petzelt, Physikalisch-Technische Bundesanstalt (Germany)
C. Bührer, Charité-Univ. Medicine Berlin (Germany)
W. Semmler, Deutsches Krebsforschungszentrum (Germany)
R. Tauber, Charité-Univ. Medizin Berlin (Germany)


© SPIE. Terms of Use
Back to Top